Clinical Trial: NCT04258033
A Study of PLB1001 in Non-small Cell Lung Cancer With c-Met Dysregulation(KUNPENG)
Status:
COMPLETEDPhase:
Phase 2| Lead Sponsor: | Beijing Pearl Biotechnology Limited Liability Company |
| Information Provided By: | Beijing Pearl Biotechnology Limited Liability Company |
| Last Update Posted: | 2026-06-05 |
Study Overview
Brief Summary
This is a Phase II, open-label, multicenter and multi-cohorts study of PLB1001 administered orally twice daily to locally advanced/metastatic NSCLC patients with c-Met dysregulation.
Official Title
A Phase II, Open-label, Multicenter and Multi-cohorts Study to Evaluate the Efficacy and Safety of PLB1001 in Advanced Non-small Cell Lung Cancer With c-Met Dysregulation
Conditions
Non-small Cell Lung Cancer
Intervention / Treatment
- Drug: PLB1001
Other Study ID Numbers
- PLB1001-II-NSCLC-01
Start Date (Actual)
2020-01-17
Primary Completion Date (Actual)
2024-05-14
Study Completion Date (Actual)
2025-06-24
Enrollment (Actual)
145
Study Type
Interventional
Phase
Phase 2
| Lead Sponsor: | Beijing Pearl Biotechnology Limited Liability Company |
| Information Provided By: | Beijing Pearl Biotechnology Limited Liability Company |
| Last Update Posted: | 2026-06-05 |
Study Overview
Brief Summary
This is a Phase II, open-label, multicenter and multi-cohorts study of PLB1001 administered orally twice daily to locally advanced/metastatic NSCLC patients with c-Met dysregulation.
Official Title
A Phase II, Open-label, Multicenter and Multi-cohorts Study to Evaluate the Efficacy and Safety of PLB1001 in Advanced Non-small Cell Lung Cancer With c-Met Dysregulation
Conditions
Non-small Cell Lung Cancer
Intervention / Treatment
- Drug: PLB1001
Other Study ID Numbers
- PLB1001-II-NSCLC-01
Start Date (Actual)
2020-01-17
Primary Completion Date (Actual)
2024-05-14
Study Completion Date (Actual)
2025-06-24
Enrollment (Actual)
145
Study Type
Interventional
Phase
Phase 2